Cwm LLC Lowers Stake in 10x Genomics, Inc. (NASDAQ:TXG)

Cwm LLC lessened its position in 10x Genomics, Inc. (NASDAQ:TXG) by 5.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 59,743 shares of the company’s stock after selling 3,418 shares during the period. Cwm LLC’s holdings in 10x Genomics were worth $3,343,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in TXG. SG Americas Securities LLC lifted its stake in shares of 10x Genomics by 204.2% in the 3rd quarter. SG Americas Securities LLC now owns 64,162 shares of the company’s stock worth $2,647,000 after acquiring an additional 43,070 shares during the period. Commonwealth Equity Services LLC lifted its stake in shares of 10x Genomics by 26.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 7,193 shares of the company’s stock worth $297,000 after acquiring an additional 1,486 shares during the period. Xponance Inc. lifted its stake in shares of 10x Genomics by 3.2% in the 3rd quarter. Xponance Inc. now owns 13,060 shares of the company’s stock worth $539,000 after acquiring an additional 400 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of 10x Genomics by 13.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,010,256 shares of the company’s stock worth $41,673,000 after acquiring an additional 122,981 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of 10x Genomics by 13.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,777 shares of the company’s stock worth $857,000 after acquiring an additional 2,419 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insider Buying and Selling at 10x Genomics

In other news, CEO Serge Saxonov sold 1,000 shares of 10x Genomics stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $49.53, for a total transaction of $49,530.00. Following the completion of the sale, the chief executive officer now directly owns 855,381 shares in the company, valued at $42,367,020.93. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Justin J. Mcanear sold 1,865 shares of 10x Genomics stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total transaction of $86,424.10. Following the completion of the sale, the chief financial officer now directly owns 95,240 shares in the company, valued at $4,413,421.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Serge Saxonov sold 1,000 shares of 10x Genomics stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $49.53, for a total transaction of $49,530.00. Following the sale, the chief executive officer now owns 855,381 shares of the company’s stock, valued at $42,367,020.93. The disclosure for this sale can be found here. In the last three months, insiders sold 12,959 shares of company stock worth $592,806. 10.65% of the stock is owned by corporate insiders.

10x Genomics Stock Performance

NASDAQ:TXG opened at $27.52 on Thursday. The firm has a 50-day moving average price of $38.54 and a two-hundred day moving average price of $42.71. 10x Genomics, Inc. has a twelve month low of $26.75 and a twelve month high of $63.57.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Thursday, February 15th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.05). 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The business had revenue of $183.98 million for the quarter, compared to analysts’ expectations of $182.73 million. During the same quarter last year, the business posted ($0.15) earnings per share. The business’s revenue was up 17.8% compared to the same quarter last year. On average, equities analysts anticipate that 10x Genomics, Inc. will post -1.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Barclays reduced their price objective on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. Stifel Nicolaus reduced their price objective on shares of 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, April 18th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $60.22.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.